Effect of lifestyle modification on hepatocellular carcinoma incidence and mortality among patients with chronic hepatitis B

被引:2
|
作者
Park, Yewan [1 ,2 ]
Kang, Danbee [3 ,4 ]
Sinn, Dong Hyun [2 ,5 ]
Kim, Hyunsoo [4 ]
Hong, Yun Soo [6 ,7 ]
Cho, Juhee [3 ,4 ,6 ,7 ]
Gwak, Geum-Youn [5 ]
机构
[1] Kyung Hee Univ Hosp, Dept Internal Med, Seoul 02447, South Korea
[2] Sungkyunkwan Univ, Dept Digital Hlth, SAIHST, Seoul 06355, South Korea
[3] Sungkyunkwan Univ, Dept Clin Res Design & Evaluat, SAIHST, Seoul 06355, South Korea
[4] Sungkyunkwan Univ, Ctr Clin Epidemiol, Samsung Med Ctr, Seoul 06351, South Korea
[5] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul 06351, South Korea
[6] Johns Hopkins Med Inst, Dept Epidemiol & Med, Baltimore, MD 21287 USA
[7] Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA
关键词
Lifestyle modification; Chronic hepatitis B; Hepatocellular carcinoma; Cancer; Mortality; CHRONIC VIRAL-HEPATITIS; COFFEE CONSUMPTION; CIGARETTE-SMOKING; LIVER-CANCER; ALCOHOL; RISK; INFECTION; DRINKING; TOBACCO;
D O I
10.3748/wjg.v29.i24.3843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Research exploring the influence of healthier lifestyle modification (LSM) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is limited. AIM To emulate a target trial to determine the effect of LSM on HCC incidence and mortality among patients with CHB by large-scale population-based observational data. METHODS Among the patients with CHB enrolled in the Korean National Health Insurance Service between January 1, 2009, and December 31, 2017, those aged >= 20 years who drank alcohol, smoked cigarettes, and were sedentary were analyzed. Exposure included at least one LSM, including alcohol abstinence, smoking cessation, and regular exercise. The primary outcome was HCC development, and the secondary outcome was liver-related mortality. We used 2:1 propensity score matching to account for covariates. RESULTS With 48766 patients in the LSM group and 103560 in the control group, the adjusted hazard ratio (HR) for incident HCC and liver-related mortality was 0.92 [95% confidence interval (CI): 0.87-0.96] and 0.92 (95%CI: 0.86-0.99) in the LSM group, respectively, compared with the control group. Among the LSM group, the adjusted HR (95%CI) for incident HCC was 0.84 (0.76-0.94), 0.87 (0.81-0.94), and 1.08 (1.00-1.16) for alcohol abstinence, smoking cessation, and regular exercise, respectively. The adjusted HR (95%CI) for liver-related mortality was 0.92 (0.80-1.06), 0.81 (0.72-0.91), and 1.15 (1.04-1.27) for alcohol abstinence, smoking cessation, and regular exercise, respectively. CONCLUSION LSM lowered the risk of HCC and mortality in patients with CHB. Thus, active LSM, particularly alcohol abstinence and smoking cessation, should be encouraged in patients with CHB. (c) The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:3843 / 3854
页数:12
相关论文
共 50 条
  • [21] Prevention of hepatocellular carcinoma in patients with chronic hepatitis B
    Conrado M Fernández-Rodríguez
    María Luisa Gutiérrez-García
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, (03) : 175 - 182
  • [22] The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
    Toyoda, H
    Kumada, T
    Nakano, S
    Takeda, I
    Sugiyama, K
    Kiriyama, S
    Sone, Y
    Hisanaga, Y
    CANCER, 2000, 88 (01) : 58 - 65
  • [23] Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B
    Tziomalos, Konstantinos
    WORLD JOURNAL OF HEPATOLOGY, 2010, 2 (03) : 91 - 93
  • [25] Incidence and natural history of hepatocellular carcinoma among patients with chronic infection with hepatitis C virus
    Ordóñez, FS
    Carrasco, JCG
    Recio, FJB
    Jiménez, AR
    Santos, PG
    López, TF
    REVISTA CLINICA ESPANOLA, 2000, 200 (07): : 360 - 366
  • [26] Anti-platelet therapy reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B
    Lee, Minjong
    Lee, Jeong-Hoon
    Oh, Sohee
    Chang, Young
    Nam, Joon Yeul
    Cho, Young Youn
    Yoo, Jeong-Ju
    Cho, Yuri
    Lee, Donghyeon
    Cho, Eun Ju
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    HEPATOLOGY, 2015, 62 : 995A - 995A
  • [27] Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance
    Kim, Gi-Ae
    Lee, Han Chu
    Kim, Min-Ju
    Ha, Yeonjung
    Park, Eui Ju
    An, Jihyun
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    JOURNAL OF HEPATOLOGY, 2015, 62 (05) : 1092 - 1099
  • [28] Nucleoside analogue treatment can not reduce the incidence of hepatocellular carcinoma in patients with chronic hepatitis B
    Yasunaka, Tetsuya
    Ikeda, Fusao
    Wada, Nozomu
    Morimoto, Yuuki
    Kuwaki, Kenji
    Takaki, Akinobu
    Yamamoto, Kazuhide
    HEPATOLOGY, 2013, 58 : 671A - 671A
  • [29] Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B
    Goh, Myung Ji
    Kang, Wonseok
    Kim, Kwang Min
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (01) : 70 - 77
  • [30] Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
    Papatheodoridis, George V.
    Dalekos, George N.
    Yurdaydin, Cihan
    Buti, Maria
    Goulis, John
    Arends, Pauline
    Sypsa, Vana
    Manolakopoulos, Spilios
    Mangia, Giampaolo
    Gatselis, Nikolaos
    Keskin, Onur
    Savvidou, Savvoula
    Hansen, Bettina E.
    Papaioannou, Christos
    Galanis, Kostantinos
    Idilman, Ramazan
    Colombo, Massimo
    Esteban, Rafael
    Janssen, Harry L. A.
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2015, 62 (02) : 363 - 370